MX351667B - Pharmaceutical compositions comprising alisporivir. - Google Patents

Pharmaceutical compositions comprising alisporivir.

Info

Publication number
MX351667B
MX351667B MX2013006525A MX2013006525A MX351667B MX 351667 B MX351667 B MX 351667B MX 2013006525 A MX2013006525 A MX 2013006525A MX 2013006525 A MX2013006525 A MX 2013006525A MX 351667 B MX351667 B MX 351667B
Authority
MX
Mexico
Prior art keywords
alisporivir
pharmaceutical compositions
based pharmaceutical
provides lipid
compositions
Prior art date
Application number
MX2013006525A
Other languages
Spanish (es)
Other versions
MX2013006525A (en
Inventor
Stowasser Frank
Goncalves Elisabete
Rapp Karin
Sutter Bertrand
Trupp Bjoern
Chabaut Sebastian
Thorens Julien
Original Assignee
Debiopharm Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45346477&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX351667(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Debiopharm Sa filed Critical Debiopharm Sa
Publication of MX2013006525A publication Critical patent/MX2013006525A/en
Publication of MX351667B publication Critical patent/MX351667B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention provides lipid-based pharmaceutical compositions comprising alisporivir.
MX2013006525A 2010-12-13 2011-12-12 Pharmaceutical compositions comprising alisporivir. MX351667B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US42249910P 2010-12-13 2010-12-13
IB2011000319 2011-02-18
IB2011000653 2011-03-25
PCT/EP2011/072463 WO2012080176A2 (en) 2010-12-13 2011-12-12 Pharmaceutical compositions

Publications (2)

Publication Number Publication Date
MX2013006525A MX2013006525A (en) 2013-08-01
MX351667B true MX351667B (en) 2017-10-24

Family

ID=45346477

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013006525A MX351667B (en) 2010-12-13 2011-12-12 Pharmaceutical compositions comprising alisporivir.

Country Status (33)

Country Link
US (2) US20140005123A1 (en)
EP (1) EP2651396B1 (en)
JP (2) JP6259288B2 (en)
KR (1) KR101928589B1 (en)
CN (2) CN103282022A (en)
AR (1) AR084235A1 (en)
AU (3) AU2011344331A1 (en)
BR (1) BR112013014606A2 (en)
CA (1) CA2819167C (en)
CL (1) CL2013001684A1 (en)
CO (1) CO6761388A2 (en)
CY (1) CY1119468T1 (en)
DK (1) DK2651396T3 (en)
EC (1) ECSP13012679A (en)
ES (1) ES2643135T3 (en)
HR (1) HRP20171485T1 (en)
HU (1) HUE036784T2 (en)
IL (1) IL226554A (en)
JO (1) JO3337B1 (en)
LT (1) LT2651396T (en)
MA (1) MA34709B1 (en)
MX (1) MX351667B (en)
MY (1) MY165088A (en)
NZ (1) NZ610950A (en)
PE (1) PE20140104A1 (en)
PL (1) PL2651396T3 (en)
PT (1) PT2651396T (en)
RU (1) RU2639482C2 (en)
SG (2) SG190894A1 (en)
SI (1) SI2651396T1 (en)
TW (1) TWI599368B (en)
WO (1) WO2012080176A2 (en)
ZA (1) ZA201303721B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2591195C2 (en) 2010-12-13 2016-07-10 Эррэй Биофарма Инк. Substituted n-(1h-indazole-4-yl) imidazole [1,2-a]pyridine-3- carboxamide compounds as inhibitors of tyrosine kinase type iii receptor
JO3337B1 (en) 2010-12-13 2019-03-13 Debiopharm Sa Pharmaceutical Compositions Comprising Alisporivir
WO2015008223A1 (en) 2013-07-17 2015-01-22 Novartis Ag Treatment of hepatitis c virus infection with alisporivir and ribavirin
WO2015136455A1 (en) 2014-03-13 2015-09-17 Novartis Ag New treatments of hepatitis c virus infection
AR114930A1 (en) * 2017-09-12 2020-11-11 Novartis Ag PHARMACEUTICAL COMPOSITION

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1274354A (en) 1956-03-10 1961-10-27 Surfactants obtained from triglycerides and polyethylene glycol
GB2222770B (en) * 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
GB9113872D0 (en) * 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
FR2697040B1 (en) 1992-10-21 1994-12-30 Ind Entreprise Protection element against noise and its use.
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
SE504582C2 (en) * 1995-07-06 1997-03-10 Gs Dev Ab Cyclosporin composition based on an L2 phase
ID25908A (en) 1998-03-06 2000-11-09 Novartis Ag EMULSION PRACTONCENTRATES CONTAINING CYCLOSPORINE OR MACROLIDES
AU3843999A (en) * 1998-05-07 1999-11-23 Elan Corporation, Plc Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems
ES2255275T3 (en) * 1998-07-01 2006-06-16 Debiopharm S.A. NEW CYCLOSPORINE WITH IMPROVED ACTIVITY PROFILE.
GB9903547D0 (en) * 1999-02-16 1999-04-07 Novartis Ag Organic compounds
GB0001928D0 (en) * 2000-01-27 2000-03-22 Novartis Ag Organic compounds
US6979672B2 (en) * 2002-12-20 2005-12-27 Polichem, S.A. Cyclosporin-based pharmaceutical compositions
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
NZ554412A (en) * 2004-10-01 2011-01-28 Debiopharm Sa Use of [D-MeAla]3-[EtVal]4-cyclosporin for the treatment of hepatitis C infection and pharmaceutical composition comprising said [D-MeAla]3-[EtVal]4-cyclosporin
KR20070087624A (en) 2004-12-23 2007-08-28 노파르티스 아게 Compositions for hcv treatment
GB0504950D0 (en) 2005-03-10 2005-04-20 Novartis Ag Organic compositions
NZ593204A (en) 2008-11-06 2013-02-22 Debio Rech Pharma Sa Cycloundecadepsipeptide compounds and use of said compounds as a medicament
JO3337B1 (en) 2010-12-13 2019-03-13 Debiopharm Sa Pharmaceutical Compositions Comprising Alisporivir

Also Published As

Publication number Publication date
WO2012080176A2 (en) 2012-06-21
SG190894A1 (en) 2013-07-31
WO2012080176A3 (en) 2012-08-09
AU2016201053B2 (en) 2017-07-13
EP2651396B1 (en) 2017-07-12
PT2651396T (en) 2017-10-18
ZA201303721B (en) 2014-04-30
HUE036784T2 (en) 2018-08-28
CA2819167A1 (en) 2012-06-21
JP2014503520A (en) 2014-02-13
SI2651396T1 (en) 2017-11-30
US10188696B2 (en) 2019-01-29
RU2013132543A (en) 2015-01-20
CN105125489B (en) 2019-04-16
CY1119468T1 (en) 2018-03-07
TWI599368B (en) 2017-09-21
ECSP13012679A (en) 2013-08-30
PL2651396T3 (en) 2017-12-29
JO3337B1 (en) 2019-03-13
US20160367624A1 (en) 2016-12-22
KR20140018858A (en) 2014-02-13
RU2639482C2 (en) 2017-12-21
MY165088A (en) 2018-02-28
AR084235A1 (en) 2013-05-02
CL2013001684A1 (en) 2014-01-10
EP2651396A2 (en) 2013-10-23
CN105125489A (en) 2015-12-09
AU2017245296A1 (en) 2017-11-02
CA2819167C (en) 2019-12-31
AU2011344331A1 (en) 2013-07-11
KR101928589B1 (en) 2018-12-12
US20140005123A1 (en) 2014-01-02
AU2016201053A1 (en) 2016-03-10
BR112013014606A2 (en) 2017-06-06
MA34709B1 (en) 2013-12-03
DK2651396T3 (en) 2017-10-23
TW201306859A (en) 2013-02-16
PE20140104A1 (en) 2014-02-04
JP2018027949A (en) 2018-02-22
IL226554A (en) 2017-12-31
MX2013006525A (en) 2013-08-01
ES2643135T3 (en) 2017-11-21
LT2651396T (en) 2017-09-25
NZ610950A (en) 2015-07-31
SG10201509833YA (en) 2016-01-28
JP6259288B2 (en) 2018-01-10
CN103282022A (en) 2013-09-04
CO6761388A2 (en) 2013-09-30
HRP20171485T1 (en) 2017-11-17

Similar Documents

Publication Publication Date Title
JOP20180102B1 (en) Pharmaceutical composition
PH12017501298A1 (en) Pesticidal compositions and processes related thereto
MX2012015188A (en) Controlled release compositions with reduced food effect.
MX340831B (en) Pesticidal compositions.
EP2681268B8 (en) Organosiloxane compositions
PH12014502398B1 (en) Pesticidal compositions and processes related thereto
IN2012DN06714A (en)
JO3755B1 (en) Testosterone formulations
IN2015DN00127A (en)
GB201017345D0 (en) Receptor antagonists
HUE031336T2 (en) Pharmaceutical compositions
TN2014000136A1 (en) Selective androgen receptor modulators
IN2012DN03404A (en)
JO3337B1 (en) Pharmaceutical Compositions Comprising Alisporivir
IN2014CN00312A (en)
HUE051133T2 (en) Pharmaceutical compositions
MX2013000539A (en) New formulations of 14 - epi -analogues of vitamin d.
IN2012DE02272A (en)
GB201012359D0 (en) Invention 6.5.10
CL2011000028S1 (en) Dispensing container
TN2013000218A1 (en) Pharmaceutical compositions comprising alisporivir
GB201015621D0 (en) Invention 30.08.10
IN2015KN00386A (en)
UA72478U (en) Use of polentar as frigoprotector
UA80618U (en) Use of n-steroylethanolamine as radiomodifier

Legal Events

Date Code Title Description
FG Grant or registration